We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+1.63%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.4B
AUM Growth
-$121M
(-8%)
Cap. Flow
-$42.7M
Cap. Flow
% of AUM
-3.06%
Top 10 Holdings %
Top 10 Hldgs %
47.37%
Holding
90
New
7
Increased
27
Reduced
20
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$26M |
| 2 |
Keros Therapeutics
KROS
|
+$18.9M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$15.4M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$14.8M |
| 5 |
FNA
Paragon 28, Inc.
FNA
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aldeyra Therapeutics
ALDX
|
+$26.2M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$25.7M |
| 3 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$16.5M |
| 4 |
Insmed
INSM
|
+$15.1M |
| 5 |
OptimizeRx
OPRX
|
+$14.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.7% |
| 2 | Communication Services | 5.48% |
| 3 | Energy | 0.15% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPNE
1
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $88.6M | 6.35% |
6,506,038
+242,778
| +4% | +$3.49M |
|
2
Prothena Corp
PRTA
$425M
| $80.2M | 5.74% |
1,622,941
+173,447
| +12% | +$9.62M |
|
|
MODN
3
DELISTED
MODEL N, INC.
MODN
| $76.5M | 5.48% |
2,547,930
+69,398
| +3% | +$2.17M |
|
|
4
AtriCure
ATRC
$1.92B
| $69.9M | 5% |
1,004,989
+357,797
| +55% | +$26M |
|
5
Tandem Diabetes Care
TNDM
$1.34B
| $62M | 4.44% |
411,784
-67,402
| -14% | -$9.1M |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$269M
| $60.9M | 4.36% |
1,000,783
+268,052
| +37% | +$14.8M |
|
7
Halozyme
HALO
$9.79B
| $60.8M | 4.35% |
1,511,843
+34,347
| +2% | +$1.28M |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $60M | 4.3% |
645,848
-314
| -0% | -$20.7K |
|
9
Omnicell
OMCL
$1.61B
| $55M | 3.94% |
304,895
-49,147
| -14% | -$8.52M |
|
10
Krystal Biotech
KRYS
$10.1B
| $47.6M | 3.41% |
680,170
+46,689
| +7% | +$2.72M |
|
|
XENT
11
DELISTED
Intersect ENT, Inc
XENT
| $46.4M | 3.32% |
1,697,834
-438,989
| -21% | -$11.9M |
|
|
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $36.9M | 2.64% |
281,701
+6,057
| +2% | +$783K |
|
13
Ultragenyx Pharmaceutical
RARE
$2.45B
| $34.6M | 2.48% |
411,313
-29,846
| -7% | -$2.43M |
|
14
Codexis
CDXS
$151M
| $34.1M | 2.44% |
1,089,150
+389,434
| +56% | +$12.8M |
|
15
Sutro Biopharma
STRO
$401M
| $33.4M | 2.39% |
224,659
+5,515
| +3% | +$988K |
|
|
16
Keros Therapeutics
KROS
$199M
| $32.3M | 2.31% |
552,098
+378,888
| +219% | +$18.9M |
|
17
Health Catalyst
HCAT
$154M
| $32.2M | 2.31% |
813,046
+18,086
| +2% | +$824K |
|
18
CareDx
CDNA
$2.26B
| $31.1M | 2.23% |
683,463
-217,007
| -24% | -$11.3M |
|
|
LITS
19
Lite Strategy Inc
LITS
$32.8M
| $30M | 2.14% |
560,871
+128,997
| +30% | +$7.2M |
|
|
CUTR
20
DELISTED
Cutera, Inc.
CUTR
| $27.1M | 1.94% |
656,873
-111,854
| -15% | -$4.59M |
|
21
Alphatec Holdings
ATEC
$1.46B
| $26.6M | 1.9% |
2,325,485
+550,817
| +31% | +$6.5M |
|
|
TPTX
22
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $26.2M | 1.88% |
549,626
+96,748
| +21% | +$4.33M |
|
23
NeoGenomics
NEO
$1.96B
| $26.1M | 1.87% |
763,907
-292,053
| -28% | -$11.4M |
|
24
Axogen
AXGN
$2.27B
| $21.4M | 1.53% |
2,285,373
+46,112
| +2% | +$553K |
|
|
25
OptimizeRx
OPRX
$114M
| $19.5M | 1.4% |
313,769
-193,615
| -38% | -$14.7M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, First Light Asset Management held 90 positions worth $1.4B, down 8% from $1.52B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management withdrew a net $42.7M in Q4 2021, closing 11 positions and reducing 20 holdings. Its most notable exit was Aldeyra Therapeutics, an estimated $26.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 81% a quarter earlier, followed by Communication Services and Energy.
Against the trend, First Light Asset Management opened a new position in BELLUS Health Inc. worth $18.7M.
- First Light Asset Management's largest Q4 2021 buy was BELLUS Health Inc.: 2,326,528 shares worth $18.7M.
- First Light Asset Management added most to AtriCure in Q4 2021, an estimated $26M increase.
- First Light Asset Management's biggest Q4 2021 reduction was Insmed, cutting an estimated $15.1M.
- First Light Asset Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $26.2M.
- First Light Asset Management's ten largest holdings make up 47% of its $1.4B portfolio in Q4 2021.
- First Light Asset Management opened 7 new positions and closed 11 in Q4 2021.
- First Light Asset Management's portfolio value fell 8% quarter-over-quarter to $1.4B.
Based on First Light Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.